malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction on a bruton's tyrosine kinase (btk) inhibitor planned or concurrent use of a host modifiers/immune-based therapies or anti-cd20 monoclonal antibody treatment participants with prior of current hematologic malignancy or solid tumor malignancy with treatment within 6 months prior to study entry note: other protocol defined inclusion/exclusion criteria may apply.

malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction on a bruton's tyrosine kinase (btk) inhibitor planned or concurrent use of a host modifiers/immune-based therapies or anti-cd20 monoclonal antibody treatment participants with prior of current hematologic malignancy or solid tumor malignancy with treatment within 6 months prior to study entry note: other protocol defined inclusion/exclusion criteria may apply.

participant is on mechanical ventilation for > 24 hours malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction on a btk inhibitor planned or concurrent use of tocilizumab participants with cancer note: other protocol defined inclusion/exclusion criteria may apply.

participant is on mechanical ventilation for > 24 hours malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction on a btk inhibitor planned or concurrent use of tocilizumab participants with cancer note: other protocol defined inclusion/exclusion criteria may apply.

1. participant is on mechanical ventilation for > 24 hours 2. malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction 3. on a btk inhibitor 4. planned or concurrent use of tocilizumab 5. participants with cancer note: other protocol defined inclusion/exclusion criteria may apply.

1. participant is on mechanical ventilation for > 24 hours 2. malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction 3. on a btk inhibitor 4. planned or concurrent use of tocilizumab 5. participants with cancer note: other protocol defined inclusion/exclusion criteria may apply.